Instrument Inactif

Communiqués PHARMING GROUP Euronext Amsterdam

Actions

NL0000377018

Produits pharmaceutiques

Cours en clôture Euronext Amsterdam Autres places de cotation
- ^EUR	-

04/06	Pharming Group N.V. annonce l'acceptation par la FDA de la nouvelle soumission de la sNDA pour Joenja (leniolisib) dans le traitement des enfants de 4 à 11 ans atteints du syndrome APDS	CI
04/06	Pharming Group : la FDA accepte la demande de mise sur le marché d'un traitement contre l'immunodéficience	MT

Communiqués

03/07	Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden	PU
03/07	Pharming N : DWS Investment GmbH - Pharming Group N.V. - Leiden	PU
05/06	Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja to treat children aged 4 to 11 years with APDS	AQ
04/06	Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS	GL
02/06	Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York	GL
28/05	Pharming Group announces results of 2026 Annual General Meeting of Shareholders	GL
26/05	Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden	PU
22/05	European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union	GL
19/05	Pharming N : Corporate Presentation - May 2026	PU
15/05	Pharming N : 1Q 2026 financial results - Download transcript	PU
08/05	Pharming N : DWS Investment GmbH - Pharming Group N.V. - Leiden	PU
07/05	Pharming N : 1Q 2026 financial results - Download presentation	PU
07/05	Pharming N : 1Q 2026 financial results - Download press release	PU
07/05	Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders	GL
07/05	Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026	GL
23/04	Pharming Group to report first quarter 2026 financial results and provide business update on May 7	GL
16/04	Pharming N : Explantory Notes - AGM 2026	PU
16/04	Pharming N : Proxy - AGM 2026	PU
16/04	Pharming N : Notice to Convene - AGM 2026	PU
16/04	Pharming Group announces the 2026 Annual General Meeting of Shareholders	GL
13/04	Pharming N : Amendment to Annual Report by Foreign Issuer (Form 20-F/A)	PU
13/04	Pharming N : Needham Virutal Healthcare Conference presentation, 13 april 2026	PU
13/04	Pharming N : Needham Virtual Healthcare Conference presentation, April 13, 2026	PU
07/04	Pharming Group to participate in April investor conferences	GL
02/04	Pharming Group announces the filing of its 2025 Annual Report and Form 20-F	GL